Navigation Links
CeloNova BioSciences Introduces a New Class of Coronary Stent: The CATANIA(TM) Coronary Stent System with NanoThin Polyzene(R)-F
Date:1/19/2008

ATLANTA, Jan. 20 /PRNewswire/ -- CeloNova BioSciences, Inc. ("CeloNova"), leading and accelerating healthcare solutions through the development of innovative medical devices, today announced breakthrough results from the ATLANTA study of the CATANIA(TM) Coronary Stent System with NanoThin Polyzene(R)-F at the 20th Annual International Symposium on Endovascular Therapy (ISET).

(Photo: http://www.newscom.com/cgi-bin/prnh/20080120/CLSU002 )

Corrado Tamburino, MD, President of the Italian Society of Interventional Cardiology, Chief of Interventional Cardiology at Ferrarotto Hospital and Full Professor of Cardiology at the University of Catania is Principal Investigator for the ATLANTA study. Dr. Tamburino noted, "I perform many angioplasties in each single day, many, and I am totally impressed by the performance of this stent in a very complex patient population. No thrombosis. Low binary restenosis. No MIs. This may be an answer to the problems we are facing with other stent systems."

The CATANIA(TM) Stent System with NanoThin Polyzene(R)-F, dubbed "The CAT" by cardiologists who have used the product, has completed CE Marking and is available for sale anywhere the CE Mark is accepted. Advantages include:

-- Early and complete vessel healing, as early as 30 days.

-- Patients can discontinue dual anti-platelet therapy after only one

month.

-- Protection from stent thrombosis

-- The Polyzene(R)-F surface treatment is bacterial-resistant

"The FDA has cautioned physicians about a small but significant increased risk of stent thrombosis for patients with drug-eluting stents. Now, Britain's National Institute for Health and Clinical Excellence is considering restrictions on DES because they are not cost-effective for most patients and because of uncertainties about safety. Polyzene(R)-F seems to solicit a positive biological response that treats the stent as accepted part of the vessel. As a result, 'The CAT' patients have excellent outcomes and can be free from the medical complications and financial burden associated with indefinite anti-platelet therapy," stated Thomas A. Gordy, President and Chief Executive Officer.

About CeloNova BioSciences, Inc.

Headquartered in Newnan, near Atlanta, Georgia, CeloNova BioSciences, Inc., is a developer of novel medical devices that are then enhanced by one of the Company's proprietary materials, Polyzene(R)-F. Polyzene(R)-F is highly lubricious, anti-inflammatory, and bacterial-resistant making it an ideal surface treatment for implanted medical devices. The Company's current products include its Embozene(TM) Color-Advanced Microspheres and the CATANIA(TM) Coronary Stent System with NanoThin Polyzene(R)-F. Other innovative devices are currently in the company's developmental pipeline. For more information, please visit http://www.celonova.com.

Contact:

Thomas A. Gordy

President and Chief Executive Officer

+1 770-502-0304


'/>"/>
SOURCE CeloNova BioSciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. CeloNova BioSciences Announces Positive Results from European Study of Embozene(TM) Microspheres for Treatment of Uterine Fibroids
2. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
3. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
4. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
5. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
6. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
7. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
8. Alacrity Biosciences Announces Positive Results from a Phase 2 Study of Its Dry Eye Treatment ALTY-0501
9. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
10. Regado Biosciences Initiates Phase IIa Clinical Study of REG1 Anticoagulation System
11. Regado Biosciences Presents Positive Data From REG1 Anticoagulation System Phase Ic Study at American Heart Association 2007 Scientific Sessions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... CORDOBA, Spain , Dec. 2, 2016 ... additional natural sources apart from those derived from C. ... Córdoba, the Universita` di Napoli Federico II , ... have created the first comprehensive, critical, integrated and unified ... The article focuses on the remarkable chemical ...
(Date:12/2/2016)...  Eli Lilly and Company (NYSE: LLY ... provide updated financial guidance for 2016 on Thursday, December ... on that day with the investment community and media ... The conference call will begin at 10 a.m. ET. ... live webcast of the conference call through a link ...
(Date:12/2/2016)... WOONSOCKET, R.I. , Dec. 2, 2016 ... hold its annual Analyst Day in New York City on Thursday, December ... the CVS Health leadership team will provide an in-depth ... and enhance shareholder value. The company will also discuss ... audio and video webcast of the event will be ...
Breaking Medicine Technology:
(Date:11/30/2016)... , ... November 30, 2016 , ... ... they now offer a comprehensive in-house dental plan for all patients. Understanding that ... a plan that gives patients a number of perks, including discounts on many ...
(Date:11/30/2016)... ... November 30, 2016 , ... Standard ... 75, an annual ranking and recognition of the largest closely held companies headquartered ... ranked from 2008-2016. In addition, Standard Process was awarded the Talent Award for ...
(Date:11/30/2016)... Chino Hills, CA (PRWEB) , ... November 30, ... ... in eating disorder and mental health treatment has announced the opening of a ... specialized residential treatment for girls with mental health issues such as severe anxiety, ...
(Date:11/30/2016)... ... November 30, 2016 , ... The Cronovo ... design wanted by today’s consumers at an affordable price, is now available on ... new watch is “a game changer” when it comes to the smartwatch. , ...
(Date:11/30/2016)... ... November 30, 2016 , ... The Valley’s ... with the addition of new North Phoenix and Chandler locations. , The new ... Mountain campus at 9327 North 3rd St, Suite 300 in Phoenix. The practice’s ...
Breaking Medicine News(10 mins):